Clinical use of aromatase inhibitors in the treatment of advanced breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 61, Issue 3-6, 1997, Pages 241-245

  Trunet, Patrick F ^a   Vreeland, Franzanne ^a   Royce, Catherine ^a   Chaudri, Hilary A ^a   Cooper, Judy ^a   Bhatnagar, Ajay S ^a  

^a Pharmaceut Div Ciba Geigy L   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; ESTROGEN; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL; TAMOXIFEN;

ADVANCED CANCER; BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

EID: 0031123310     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00249-X     Document Type: Conference Paper

References (36)

1. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocr. Rev. 11:1990;221-265.
2. Miller W.R., Forrest A.P.M. Oestradiol synthesis from C19 steroids by human breast cancers. Br. J. Cancer. 33:1976;116-118.
3. Lipton A., Santner S.J., Santen R.J., Harvey H.A., Feil P.D., White-Hersey D., Bartholomew M.J., Antle C.E. Aromatase activity in primary and metastatic breast cancer. Cancer. 59:1987;797-802.
4. Dowsett M., Cunningham D.C., Stein R.C., Evan S., Dehennin L., Hedley A., Coombes R.C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 49:1989;1306-1312.
5. Höffken K., Jonat W., Possinger K., Kolbel M., Kunz T.H., Wagner H., Becher R., Callies R., Schmidt C.G. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: phase II study. J. Clin. Oncol. 8:1990;875-880.
6. Stein R.C., Dowsett M., Hedley A., Davenport J., Etazet J.C., Ford H.T., Coombes R.C. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother. Pharmacol. 26:1990;75-78.
7. Coombes R.C., Hughes S.W.M., Dowsett M. 4-Hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. Eur. J. Cancer. 28A:1992;1941-1945.
8. Wiseman L.R., McTavish D. Formestane: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs. 45:1993;66-84.
9. Pérez Carrion R., Alberola V., Calabresi F., Michel R.Th., Santos R., Delozier T., Goss P., Mauriac L., Feuilhade F., Freue M., Pannuti F., Van Belle S., Martinez J., Wehrle E., Royce C.M. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. 5:1994;S19-S24.
10. Rose C., Freue M., Kjaer M., Boni C., Jänicke F., Coombes C., Willemse Ph.B., Van Belle S., Pérez Carrion R., Jolivet J., Ibarra de Palacios P. An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients. Eur. J. Cancer. 32A:(Suppl. 2):1996;49.
11. Steele R.E., Mellor L.B., Sawyer W.K., Wasvary J.M., Browne L.J. In-vitro and in-vivo studies demonstrating potent and selective oestrogen inhibition with the non-steroidal aromatase inhibitor CGS 16949 A. Steroids. 50:1987;147-161.
12. Santen R.J., Demers L.M., Adlercreutz H., Harvey H.A., Santner S., Sanders S., Lipton A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J. Clin. Endocr. Metab. 68:1989;99-106.
13. Dowsett M., Stein R.C., Metha A., Coombes R.C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin. Endocr. 32:1990;623-634.
14. Demers L.M., Melby J.C., Wilson T.E., Lipton A., Harvey H.A., Santen R.J. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin. Endocr. Metab. 70:1990;1162-1166.
15. Trunet P.F., Mueller Ph., Girard F., Aupetit B., Bhatnagar A.S., Zoghbi F., Ezzet F., Ménard J. The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J. Clin. Endocr. Metab. 74:1992;571-576.
16. Höffken K., Chacon R., Dombernowsky P., Goss P., Willemse P., Engan T., Bonte J., Tubiana-Hulin M., Lopez-Lopez J.J., Elomaa I., Chaudri H., Trunet P.F. Fadrozole hydrochloride (CGS 16949 A), a double-blind dose-finding study in postmenopausal patients with advanced breast cancer. Ann. Oncol. 3:(Suppl. 5):1992;76.
17. Raats J.I., Falkson G., Falkson H.C. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J. Clin. Oncol. 10:1992;111-116.
18. Bonnefoi H.R., Smith I.E., Dowsett M., Trunet P.F., Houston S.J., Da Luz R.J., Rubens R.D., Coombes R.C., Powles T.J. Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br. J. Cancer. 73:1996;539-542.
19. Stein R.C., Dowsett M., Davenport J., Hedley A., Ford H.T., Gazet J.C., Coombes R.C. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res. 50:1990;1381-1384.
20. Dowsett M., Smithers D., Moore J., Trunet P.F., Coombes R.C., Powles T.J., Rubens R., Smith I.E. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur. J. Cancer. 30A:1994;1453-1458.
21. Lønning P.E., Jacobs S., Jones A., Haynes B., Powles T., Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br. J. Cancer. 63:1991;789-793.
22. Buzdar A.U., Smith R., Vogel Bonomi P., Keller A.M., Favis G., Mulagha M., Cooper J. Fadrozole HCl (CGS 16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multi-institutional trials. for the Multi-Institutional Trialist Collaborative Study Group Cancer. 77:1996;2503-2513.
23. Bhatnagar A.S., Häusler A., Schieweck K., Lang M., Browman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Molec. Biol. 37:1990;1021-1027.
24. Bhatnagar A.S., Häusler A., Schieweck K. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J. Enzyme Inhib. 4:1990;179-186.
25. Trunet P.F., Mueller Ph., Bhatnagar A.S., Dickes I., Monnet G., White G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J. Clin. Endocr. Metab. 77:1993;319-323.
26. Iveson T.J., Smith I.E., Ahern J, Smithers D.A., Trunet P.F., Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocr. Metab. 77:1993;324-331.
27. Santen R.J., Worgul T.J., Samojlik E., Interrante A., Boucher A.E., Lipton A., Harvey H.A., White D.S., Smart E., Cox C. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N. Engl. J. Med. 305:1981;545-551.
28. Iveson T.J., Smith I.E., Ahern J., Smithers D.A., Trunet P.F., Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53:1993;266-270.
29. Lipton A., Demers L.M., Harvey H.A., Kambic K.B., Grossberg H., Brady C., Adlercreutz H., Trunet P.F., Santen R.J. Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 75:1995;2132-2138.
30. Dowsett M., Jones A., Johnston S.R.D., Jacobs S., Trunet P.F., Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with advanced breast cancer. Clin. Cancer Res. 1:1995;1511-1515.
31. Bisagni G., Cocconi G., Scaglione F., Fraschini F., Pfister Ch., Trunet P.F. Letrozole, a new oral nonsteroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann. Oncol. 7:1996;99-102.
32. Tominaga T., Ohashi Y., Abe R., Yoshida M., Koyama H., Nomura Y., Bhatnagar A.S. Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer. Eur. J. Cancer. 31A:1995;S81.
33. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W., Gardin G., Gudgeon A., Chaudri H.A., Hornberger U. Double-blind trial in postmenopausal women with advanced breast cancer showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (abstract 64). for the Letrozole International Trial Group (AR/BC2) Philadelphia Proceedings of ASCO. 1996;100.
34. Rose C., Mouridsen H.T. Endocrine therapy of advanced breast cancer. Acta Oncol. 27:1988;721-728.
35. Jonat W., Howell A., Blomqvist Eiermann W., Winblad G., Tyrell C., Mauriac L., Roche H., Lundgren S., Hellmund R., Azab M. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex®) with megestrol acetate in postmenopausal women with advanced breast cancer. on behalf of the Arimidex Study Group Eur. J. Cancer. 32A:1996;404-412.
36. Santen R.J. Editorial: estrogen synthesis inhibitors: from "off the rack" to haute couture. J. Clin. Endocr. Metab. 77:1993;316-318.